Novartis, a big pharma company is paying Genmab $2 million up front as part of a biopharma collaboration to develop bispecific antibodies based on the latter’s DuoBody technology against two disease target combinations selected by Novartis.
Under terms of this biopharma deal Genmab will develop panels of bispecific antibodies, and Novartis will be responsible for fully funding all research work.
If all milestones of the biopharma collaboration are met Genmab could earn about $175 million through the partnership, excluding research funding and royalties.
For further deal information visit Current Agreements (subscription required)
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
Read: Big pharma deal news- latest deal news for top 50 pharma / big pharma companies
Report: Practical Guide to Finding Partners
Report:Partnering Deals and Alliances with Novartis
Report: Bigpharma Partnering Yearbook 2013
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity